FACTBOX-Biggest changes in Nasdaq short interest

Tue Feb 9, 2010 4:18pm EST

 NEW YORK, Feb 9 (Reuters) - Short interest on the Nasdaq rose 2.3 percent
in late January, the exchange said on Tuesday, suggesting an increase in
bearish sentiment in that stock market. For story see [ID:nNLA9DE60G].
 Below are the five Nasdaq stocks that experienced the largest increases and
decreases in their short positions from mid to late January, according to
information released by the exchange.
 The five companies with the largest overall short positions are also
listed.
 The latest date is as of Jan. 29, while the previous period's data is as of
Jan. 15.
COMPANY                       JAN 29        JAN 15     NET CHANGE  PCT CHANGE
-----------------------------------------------------------------------------
FIVE BIGGEST INCREASES:
Cell Therapeutics (CTIC.O)  82,141,576    54,385,160   27,756,416    51.04
3Com Corporation COMS.O   25,694,026    15,019,816   10,674,210    71.07
Intel Corporation (INTC.O)  56,387,112    46,735,907    9,651,205    20.65
Applied Materials (AMAT.O)  31,546,696    22,884,328    8,662,368    37.85
LM Ericsson (ERIC.O)        53,337,123    45,431,923    7,905,200    17.4
FIVE BIGGEST DECREASES:
Micron Technology (MU.O)    61,397,971    71,565,344  -10,167,373   -14.21
Cisco Systems Inc (CSCO.O)  32,486,374    39,954,728   -7,468,354   -18.69
Comcast Corp (CMCSA.O)      42,632,950    49,346,203   -6,713,253   -13.6
Huntington Bncshrs (HBAN.O) 30,152,462    35,934,363   -5,781,901   -16.09
E*TRADE Fin Corp (ETFC.O)   80,983,984    85,764,240   -4,780,256    -5.57
FIVE BIGGEST POSITIONS:
Level 3 Comms Inc LVLT.O 103,942,712    99,859,495    4,083,217     4.09
Cell Therapeutics (CTIC.O)  82,141,576    54,385,160   27,756,416    51.04
E*TRADE Fin Corp (ETFC.O)   80,983,984    85,764,240   -4,780,256    -5.57
Mylan Inc (MYL.O)           74,701,700    72,441,450    2,260,250     3.12
Palm Inc PALM.O           73,353,770    73,881,910     -528,140    -0.71
Source: Nasdaq data as of Jan. 29, Reuters Estimates
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.